An in vivo assessment of the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults.
An in vivo assessment of the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults.
复制标题
DOI：
10.1371/journal.pone.0187964
复制
发表时间：
2017
期刊：
影响因子：
3.7
通讯作者：
Gibson GR
中科院分区：
文献类型：
--
作者：
Costabile A;Buttarazzi I;Kolida S;Quercia S;Baldini J;Swann JR;Brigidi P;Gibson GR
冠心病（CHD）是工业化国家死亡和残疾的主要原因之一，血胆固醇升高是一个既定的风险因素。降低原发性高胆固醇血症人群的血浆总胆固醇可能降低CHD发病率。本研究调查了植物乳杆菌ECGC 13110402的胆固醇降低能力，选择其高胆盐水解酶活性的菌株，在49个正常至轻度高胆固醇血症的成年人。主要疗效结局包括对血脂（总胆固醇（TC）、低密度脂蛋白（LDL-C）、高密度脂蛋白（HDL-C）和三酰甘油（TAG））、炎症生物标志物和胃肠道副作用的发生/严重程度的影响，以确定干预的安全性和耐受性。次要结局包括血压、免疫生物标志物、肠道微生物群特征和代谢组变化。该研究以平行、双盲、安慰剂对照、随机化设计进行，其中活性组每天两次摄入2x 109 CFU包封的植物乳杆菌ECGC 13110402。在0-12周期间，每日摄入活性治疗导致基线TC<5 mM的志愿者的LDL-C在统计学上显著降低（13.9%，P = 0.030），在0-6周期间，基线TC≥ 6 mM的志愿者的TC显著降低在6-12周期间，60岁以上人群中TAG显著降低（53.9%，P = 0.030），HDL-C显著升高（14.7%，P = 0.007）。在6-12周期间，在活性研究组中也观察到收缩压统计学显著降低（6.6%，P = 0.003）。研究期间未观察到对胃肠道功能的影响和副作用。与血液和尿液代谢组学分析相似，粪便宏基因组学在活性或安慰剂摄入后没有显示出显著变化。这项研究的结果表明，植物乳杆菌ECGC 13110402是一种耐受性良好的天然益生菌，可用作现有治疗的替代或补充，以降低心血管风险。试验注册：Clinical trials.gov NCT 03263104
Coronary heart disease (CHD) is one of the major causes of death and disability in industrialised countries, with elevated blood cholesterol an established risk factor. Total plasma cholesterol reduction in populations suffering from primary hypercholesterolemia may lower CHD incidence. This study investigated the cholesterol reducing capacity of Lactobacillus plantarum ECGC 13110402, a strain selected for its high bile salt hydrolase activity, in 49 normal to mildly hypercholesterolaemic adults. Primary efficacy outcomes included effect on blood lipids (total cholesterol (TC), low density lipoproteins (LDL-C), high density lipoproteins (HDL-C) and triacylgycerides (TAG), inflammatory biomarkers and occurrence/severity of gastrointestinal side effects to establish safety and tolerance of the intervention. Secondary outcomes included blood pressure, immune biomarkers, gut microbiota characterisation and metabonome changes. The study was run in a parallel, double blind, placebo controlled, randomised design in which the active group ingested 2x109 CFU encapsulated Lactobacillus plantarum ECGC 13110402 twice daily. Daily ingestion of the active treatment resulted in a statistically significant reduction in LDL-C in volunteers with baseline TC<5mM during the 0–12 week period (13.9%, P = 0.030), a significant reduction in TC in volunteers with baseline TC≥6mM in the 0–6 week period (37.6%, P = 0.045), a significant decrease in TAG (53.9% P = 0.030) and an increase in HDL-C (14.7%, P = 0.007) in the over 60 years population in the 6–12 week period. A statistically significant reduction in systolic blood pressure was also observed across the active study group in the 6-12-week period (6.6%, P = 0.003). No impact on gastrointestinal function and side effects was observed during the study. Similar to blood and urine metabonomic analyses, faecal metagenomics did not reveal significant changes upon active or placebo intake. The results of this study suggest that Lactobacillus plantarum ECGC 13110402 is a well-tolerated, natural probiotic, that may be used as an alternative or supplement to existing treatments to reduce cardiovascular risk. Trial registration: Clinical trials.gov NCT03263104
登录
查看更多内容
影响因子：
4.5
作者：
Laitinen K;Gylling H
通讯作者：
Gylling H
影响因子：
3.7
作者：
Biagi E;Nylund L;Candela M;Ostan R;Bucci L;Pini E;Nikkïla J;Monti D;Satokari R;Franceschi C;Brigidi P;De Vos W
通讯作者：
De Vos W
影响因子：
--
作者：
Jones ML;Chen H;Ouyang W;Metz T;Prakash S
通讯作者：
Prakash S
影响因子：
3.5
作者：
Lye, H. -S.;Rusul, G.;Liong, M. -T.
通讯作者：
Liong, M. -T.
影响因子：
120.7
作者：
Jackevicius, CA;Mamdami, M;Tu, JV
通讯作者：
Tu, JV